Combined administration of serogroup B meningococcal vaccine and conjugated serogroup C meningococcal vaccine is safe and immunogenic in college students

Epidemiology and Infection

Volumn 136, Issue 6, 2008, Pages 790-799

  Holmes, John D ^a   Martin, D ^b   Ramsay, C ^c   Ypma, E ^d   Oster, P ^e  

^a Public Health South   (New Zealand)

^b INSTITUTE OF ENVIRONMENTAL SCIENCE AND RESEARCH   (New Zealand)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d Novartis Vaccines BV Amsterdam   (Netherlands)

^e NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL POLYSACCHARIDE; MENINGOCOCCUS VACCINE; OUTER MEMBRANE PROTEIN;

ADULT; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; COLLEGE STUDENT; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALAISE; MENINGOCOCCOSIS; MONOTHERAPY; MOUTH TEMPERATURE; MYALGIA; NAUSEA; NEISSERIA MENINGITIDIS; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SERUM BACTERICIDAL ACTIVITY; SIDE EFFECT; VACCINATION;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; CARRIER STATE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; MICROBIAL VIABILITY; PHARYNX; PREVALENCE; STUDENTS; VACCINES, CONJUGATE;

EID: 42149132051     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268807009211     Document Type: Article

References (14)

1. Dyet K, et al. New Zealand's epidemic of meningococcal disease described using molecular analysis: Implications for vaccine delivery. Vaccine 2005; 23: 2228-2230.
2. Martin D, McDowell R. The Epidemiology of Meningococcal Disease in New Zealand in 2003. Report prepared for the Ministry of Health by the Institute of Environmental Science and Research Limited (ESR). Wellington: Ministry of Health, 2004 (http://www.moh.govt.nz/moh.nsf/0/ C088F437895D6-DC8CC256ED1000B2539/$File/ epidemiologyofmeningococcaldiseas.e2003.pdf). Accessed 3 July 2007.
3. Oster P, et al. MeNZB™: A safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 2005; 23: 2191-2196.
4. Aaberge IS, et al. Combined administration of meningococcal serogroup B outer membrane vesicle vaccine and conjugated serogroup C vaccine indicated for prevention of meningococcal disease is safe and immunogenic. Clinical and Diagnostic Laboratory Immunology 2005; 12: 599-605.
5. Neal KR, et al. Changing carriage rate of Neisseria meningitidis among university students during the first week of term: cross sectional study. British Medical Journal 2000; 320: 846-849.
6. Imrey PB, et al. Meningococcal carriage, alcohol consumption, and campus bar patronage in a serogroup C meningococcal disease outbreak. Journal of Clinical Microbiology 1995; 33: 3133-3137.
7. Bruce MG, et al. Risk factors for meningococcal disease in college students. Journal of the American Medical Association 2001; 286: 688-693.
8. Caugant DA, et al. Asymptomatic carriage of Neisseria meningitidis in a randomly gampled population. Journal of Clinical Microbiology 1994; 32: 323-330.
9. Harrison LH, et al. Invasive meningococcal disease in adolescents and young adults. Journal of the American Medical Association 2001; 286: 694-699.
10. Bisno AL, et al. Diagnosis and management of group A streptococcal pharyngitis: A practice guideline. Infectious Diseases Society of America. Clinical Infectious Diseases 1997; 25: 574-583.
11. Martin DL, et al. Validation of the serum bactericidal assay for measurement of functional antibodies against group B meningococci associated with vaccine trials. Vaccine 2005; 23: 2218-2221.
12. Santos GF, et al. Importance of complement source in measuring meningococcal bactericidal titres. Clinical and Diagnostic Laboratory Immunology 2001; 8: 616-623.
13. Maslanka SE, et al. Standardization and a multi-laboratory comparison of Neisseria meningitidis sero-group A and C serum bactericidal assays. Clinical and Diagnostic Laboratory Immunology 1997; 4: 156-167.
14. Kurstak E. Progress in enzyme immunoassays: Production of reagents, experimental design, and interpretation. Bulletin of the WHO 1985; 63: 793-811.